– USA, NY – BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the appointment of Dr. Ravindra Majeti, Chief of Hematology, Stanford University, to the Board of Directors.
In 2014, Dr. Majeti co-founded Forty-Seven, Inc., a clinical-stage immuno-oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford. In March 2020, Gilead acquired Forty Seven for $4.9 billion.
“We are honored to have Dr. Majeti join our Board,” said CEO, Dr. Lan Huang. “His guidance will help the Company to translate solid science into business value, as evidenced by his work with Forty Seven. He led his company to become a highly valuable, innovative oncology division for Gilead.”
He added: “In addition, Dr. Majeti’s expertise and clinical experience in hematological cancer will help us to further develop Plinabulin for the chemotherapy-induced neutropenia indication, especially for patients suffering from hematologic cancer. We look forward to working closely with Dr. Majeti to take BeyondSpring to the next level.”
About Dr. Ravindra Majeti
Dr. Majeti currently serves as Chief, Division of Hematology, at Standard University, a position that he has held since 2017. He is also Co-Director of the Lymphoma and Leukemia Program at Stanford Cancer Institute, as well as Professor of Medicine, Hematology.
“I believe in working with people who share my values of enhancing the practice of medicine and improving the care of patients with cancer,” said Dr. Majeti. “BeyondSpring is an innovative, data-driven and patient-oriented organization that is working diligently to create a new standard of care for cancer patients, and I am excited to join the Board. Just like Forty-Seven, BeyondSpring’s strong science, coupled with its dedicated, experienced management team, will transform cancer care as we know it today and improve the global biopharmaceutical space as a whole in the near future.”
Dr. Majeti received his A.B. in biochemical sciences from Harvard University and his Ph.D. and M.D. from the University of California, San Francisco. He completed his residency in internal medicine at Brigham and Women’s Hospital and his fellowship in hematology at Stanford.
About BeyondSpring
Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia, the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway.
For more information: https://www.beyondspringpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
